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CytokineMultifocal motor neuropathy (MMN) and progressive muscular atrophy (PMA) are associated with IgM
monoclonal gammopathy or the presence IgM anti-GM1-antibodies. To further investigate the pathophysiology
of MMN and PMAwe determined concentrations of 16mainly B-cell associated inﬂammatory markers in serum
from 25 patients with MMN, 55 patients with PMA, 25 patients with amyotrophic lateral sclerosis (ALS) and
50 healthy controls. Median serum concentrations of the 16 tested cytokines and chemokines were not
signiﬁcantly increased in patients with MMN or patients with PMA, irrespective of the presence of IgM
monoclonal gammopathy or high IgM anti-GM1 antibodies. These results argue against a systemic B-cell
mediated immune response underlying the pathogenesis of MMN and PMA.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Multifocal motor neuropathy (MMN) and progressive muscular
atrophy (PMA) share clinical characteristics of progressive muscle
weakness and atrophy. MMN is an immune-mediated neuropathy
characterized by nerve conduction block and is amenable to treatment
with intravenous immunoglobulin (IVIg) (Vlam et al., 2011). PMA is a
heterogeneous neurodegenerative disorder with a natural history rang-
ing from rapidly progressive with ensuing respiratory insufﬁciency
within years to slowly progressive in decades (Van den Berg-Vos et al.,
2009; Visser et al., 2007). The association of IgM anti-GM1 antibodies
with MMN is well established and these antibodies can be detected in
approximately 50% of patients (Cats et al., 2010). We recently found
that both MMN and PMA, but not amyotrophic lateral sclerosis (ALS),
were associated with IgM monoclonal gammopathy and high titers
of IgM anti-GM1 antibodies were also present in 11% of patients
with PMA (Vlam et al., 2015). Moreover, patients with PMA and IgM
monoclonal gammopathy and/or high IgM anti-GM1 antibodies tended
to have a more favorable disease course (Vlam et al., 2015). The
presence of IgMmonoclonal gammopathy and IgManti-GM1 antibodies
in patients with MMN and a subgroup of PMA may suggest common
pathogenic mechanisms, in particular the activation of speciﬁc B-cells.
The aim of this study was to further investigate the role of B-cells
in the pathogenesis of MMN and PMA. We therefore determinednus, Department of Neurology
rglaan 100, 3508 GA Utrecht,
an der Pol).circulating protein concentrations relevant for B-cell function in serum
of patients with MMN and PMA with and without IgM monoclonal
gammopathy or IgM anti-GM1 antibodies, patients with ALS and
healthy controls.
2. Methods
2.1. Patients and controls
We included 55 patients with PMA of whom 14 (25%) had an IgM
monoclonal gammopathy or IgM anti-GM1-antibodies (PMA+), 25
patients with MMN of whom 14 (56%) had an IgM monoclonal
gammopathy or IgM anti-GM1-antibodies, 25 patients with ALS and a
total of 50 healthy controls. Sera with IgM anti-GM1-antibodies of
1:400 or higher were considered positive since these high antibody
titers are known to be speciﬁcally associated with MMN whereas
lower antibody titers can occasionally also be found in sera fromhealthy
controls (Cats et al., 2010). The healthy controls were age and gender
matched to the corresponding disease phenotype. Diagnostic criteria
were described previously (Vlam et al., 2015). Demographic features,
clinical characteristics and survival were recorded. Exclusion criteria
for patients and controls included diabetes mellitus, since high
blood glucose levels induce cytokine release (Gonzalez et al., 2012;
Shanmugam et al., 2003) and IVIg treatment less than six months
prior to blood sampling, since IVIg is known to modulate cytokine
production (Andersson et al., 1996; Murakami et al., 2012). Since
cytokine levels decrease after multiple freeze–thaw cycles and
cytokines are known to degrade over time, especially when storage
time exceeds three years (de Jager et al., 2009), we selected recently















Gender, male 10 (71) 23 (92) 29 (71) 18 (72) 20 (80) 22 (88)
Age at inclusion, years 70 (41–81) 53 (25–74) 65 (39–82) 68 (34–83) 67 (36–83) 53 (32–79)
Age at onset, years 60 (33–78) 41 (22–68) 57 (26–75) 67 (34–81) – –
Site of onset
Bulbar 0 0 0 7 (28) – –
Cervical 9 (64) 17 (68) 26 (63) 12 (48)
Lumbosacral 5 (36) 8 (32) 15 (37) 6 (24)
Disease duration, years 10 (1–38) 9 (1–49) 8 (1–29) 2 (1–6) – –
Mortality, March 1, 2013 3 (21) 0 11 (27) 12 (48) – –
Data are median (range) or number (%). Abbreviations; PMA+/− : progressive spinal muscular atrophy with and without IgM anti-GM1 antibodies or IgM monoclonal gammopathy
respectively, MMN: multifocal motor neuropathy, ALS: amyotrophic lateral sclerosis, CP: healthy controls, age, gender and storage time matched to PMA and ALS patients, CM: healthy
controls, age, gender and storage time matched to MMN patients.
2 L. Vlam et al. / Journal of Neuroimmunology 286 (2015) 1–4before. Moreover, the serum samples of the healthy controls were
matched for freezer storage time to the PMA, ALS and MMN samples.
The Medical Ethical Committee of the University Medical Center
Utrecht approved the study protocol and all subjects gave written
informed consent.
2.2. Cytokine assays
B-cell activating factor (BAFF), a proliferation inducing ligand (APRIL),
interleukin 2 (IL-2), IL-4, IL-6, IL-7, IL-8, IL-10, IL-12, IL-21, tumor necrosis
factor α (TNF-α), interferon α (IFN-α), IFN-γ, granulocyte colony-
stimulating factor (G-CSF), chemokine (C-X-C motif) ligand 13 (CXCL
13) and vascular endothelial growth factor (VEGF) were selected as the
inﬂammatory markers of interest (Acosta-Rodriguez et al., 2007;
Crampton et al., 2010). BAFF and APRIL concentrations were determined
using a standardized pre-coated enzyme-linked immunosorbent assay
(ELISA) (eBioscience, Vienna, Austria) according to the manufacturer's
instructions. The remaining proteins were measured by an in house
developed and validated panel using xMAP technology (Luminex, Austin,
TX USA) as described previously (de Jager et al., 2007). Acquisition was
done with xPonent 4.2 (Luminex) and analysis with Bioplex manager
6.1.1 (Biorad Laboratories, Herfordshire, UK).
2.3. Statistical analysis
Chi-square test or Mann–Whitney U test was used to investigate
differences in gender and age between patients and controls. CytokineFig. 1.Heatmap of cytokine proﬁles. Heatmapwasmadewith the diagnosis ﬁxed. The black bar
50healthy controls. A color proﬁlewasmade to show the cytokine proﬁle of each individual usin
and blue a minimum cytokine concentration (all pg/ml). There was no clustering of any of theconcentrations in the patient groups and controls were compared
with Mann–Whitney U test (SPSS for Windows, Chicago, IL USA).
A p-value b0.05 was considered statistically signiﬁcant. To investi-
gate whether a single cytokine contributed to disease susceptibility
a cluster analysis was performed (Omniviz v6.1 Instem scientiﬁc,
Staffordshire, UK).3. Results
3.1. Patients and controls
Baseline characteristics are shown in Table 1. Median age and
gender did not differ between patients with PMA+, PMA−, ALS
and controls, and between MMN patients and matched controls.
Nerve conduction studies in patients with MMN showed a probable
(compound muscle action potential (CMAP) area reduction of
30–50% in an arm nerve) (12%) or deﬁnite (area reduction of at
least 50%) (88%) conduction block (Van Asseldonk et al., 2003).
Only two MMN patients had no signs of axon loss, deﬁned as normal
distal CMAP amplitudes of themedian, ulnar, radial, musculocutaneous,
peroneal, and tibial nerves on both sides (Van Asseldonk et al., 2003).
Serum of 12 MMN patients (50%) contained IgM anti-GM1 antibod-
ies with titres ≥1:400 and 2 MMN patients had a detectable IgM
monoclonal protein. Of the PMA patients, 7 had a IgM monoclonal
gammopathy, 3 patients had high IgM anti-GM1 antibodies and 4
patients had both.represents the 14 PMA+patients, the gray bar the 25MMNpatients and thewhite bar the
gminimal andmaximal expression normalization per protein; red represents amaximum
tested cytokines among the patient subgroups.



























































Fig. 2. Serum IL-2, IL-6, TNF-α and G-CSF levels in patients with MMN, PMA, ALS and healthy controls. None of the serum cytokine levels were signiﬁcantly elevated in the MMN or PMA
patients compared to their matched healthy and disease controls.
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None of the tested median serum protein levels were signiﬁcantly
elevated in patients withMMNor patients with PMA and IgMmonoclo-
nal gammopathy or high IgM anti-GM1 antibodies compared to healthy
and disease controls. A heatmap of all markers is displayed in Fig. 1.
Hierarchical cluster analysis of the different cytokines for the MMN
patients, PMA+ patients and healthy controls revealed no signiﬁcant
clusters (data not shown). Cytokine proﬁles between MMN patients
with and without IgM anti-GM1 antibody titres ≥1:400 did not differ.
Because the IL-6 concentration tended to be slightly higher in the
PMA+ patients (Fig. 2), we performed a sub-analysis comparing the 2
MMN and 11 PMA patients with IgM monoclonal gammopathy com-
bined to the PMA matched healthy controls. There was no difference
in median IL-6 levels between the subgroups (4.8 vs 3.0 p = 0.2). We
could not corroborateﬁndings of increased IL-2, TNF-α andG-CSF levels
(Furukawa et al., 2014; Terenghi et al., 2006) (Fig. 2).4. Discussion
Werecently reported the association of IgMmonoclonal gammopathy
with bothMMN and PMA (Vlam et al., 2015), suggesting that similar dis-
ease mechanisms may underlie these disorders. In this study we investi-
gated whether concentrations of speciﬁc cytokines that are associated
with B-cell function are increased in serum from patients with MMN
and PMA. We applied strict selection criteria for the used serum samples
andmatched our controls for age and gender to our patients to reduce the
possibility of spurious associations (Andersson et al., 1996; de Jager et al.,
2009; Gonzalez et al., 2012; Murakami et al., 2012; Shanmugam et al.,
2003).We did not ﬁnd signiﬁcant differences in any of the 16 tested cyto-
kine levels between the patient groups and healthy controls.
Our ﬁndings are in line with the study by Terenghi et al. who also
found comparable cytokine concentrations in 22 patients with MMN
and healthy controls (Terenghi et al., 2006), but contradict recent ﬁnd-
ing by others, who reported elevated serum IL-1Ra, IL-2, G-CSF, TNF-a,
and TNFR1 levels in 16 patients with MMN compared to 15 patients
with other non-inﬂammatory neurological diseases (Furukawa et al.,2014). They also found signiﬁcantly increased levels of G-CSF and
TNF-a in patients with MMN compared to patients with ALS, and in
the 11 MMN patients with ‘focal demyelination’ (Furukawa et al.,
2014). Serum TNF-a levels in the MMN patients with decreased
distal CMAP amplitudes tended to be higher than those in the non-
decreased CMAP group (Furukawa et al., 2014). All of our included
MMNpatients – in linewith diagnostic consensus criteria – had conduc-
tion block, i.e. focal demyelination, and only two patients had no signs of
axonal loss. We were therefore unable to corroborate the previously
reported results, although it seems unlikely that the presence of focal
demyelination can be explained by the presence of speciﬁc cytokines.
Our study does not provide evidence for a systemic B-cell mediated
immune response inMMNandPMA+, as has been reported in other in-
ﬂammatory neurological disorders such asmultiple sclerosis, optic neu-
romyelitis and anti-MAGneuropathy.We cannot exclude the possibility
that MMN and PMA are different from these prototypical neurological
inﬂammatory disorders, in the sense that they are characterized by
very localized, low-grade inﬂammatory processes. This may ultimately
damage motor neurons or axons, but may not be reﬂected in increased
systemic cytokine levels. Alternatively, the presence of monoclonal
gammopathy may be secondary to other disease mechanisms such
as increased motor neuron and axon loss, although we ﬁnd this less
likely since we did not ﬁnd an increased prevalence of monoclonal
gammopathy in patients with ALS (Vlam et al., 2015).
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